Nitric oxide-driven nanomotors with bowl-shaped mesoporous silica for targeted thrombolysis

Tao, Yingfang; Li, Xiaoyun; Wu, Ziyu; Chen, Chenglong; Tan, Kaiyuan; Wan, Mimi; Zhou, Min; Mao, Chun

doi:10.1016/j.jcis.2021.12.065

Cited by 27 publications

(15 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Because of the excessive blood flow rate, the drug utilization rate at the thrombus site is low in traditional therapy. To solve this problem, Tao et al developed a biocompatible NO-driven silica nanomotor by loading L-arginine (LA) and thrombolytic drug urokinase (UK) in bowl-shaped mesoporous silica NPs (MS) and modifying the arginine–glycine–aspartic acid (RGD) polypeptide on the surface of NPs for targeting the thrombus surface ( Figure 7 ) [ 110 ]. The loaded L-arginine can be oxidized by excessive ROS in the thrombus microenvironment to generate NO, thus decreasing oxidative stress in inflammatory endothelial cells by eliminating ROS.…”

Section: Application Of No-releasing Biomaterials Platforms In Cvd Tr...mentioning

confidence: 99%

See 1 more Smart Citation

Nitric Oxide-Releasing Platforms for Treating Cardiovascular Disease

Wang

et al. 2022

Pharmaceutics

View full text Add to dashboard Cite

Cardiovascular disease (CVD) is the first leading cause of death globally. Nitric oxide (NO) is an important signaling molecule that mediates diverse processes in the cardiovascular system, thereby providing a fundamental basis for NO-based therapy of CVD. At present, numerous prodrugs have been developed to release NO in vivo. However, the clinical application of these prodrugs still faces many problems, including the low payloads, burst release, and non-controlled delivery. To address these, various biomaterial-based platforms have been developed as the carriers to deliver NO to the targeted tissues in a controlled and sustained manner. This review aims to summarize recent developments of various therapeutic platforms, engineered to release NO for the treatment of CVD. In addition, two potential strategies to improve the effectiveness of existing NO therapy are also discussed, including the combination of NO-releasing platforms and either hydrogen sulfide-based therapy or stem cell therapy. Hopefully, some NO-releasing platforms may provide important therapeutic benefits for CVD.

show abstract

Section: Application Of No-releasing Biomaterials Platforms In Cvd Tr...mentioning

confidence: 99%

“… The preparation process of MS/LA/RGD/UK nanomotors and their application in the treatment of thrombosis. Reproduced with permission from [ 110 ], Journal of Colloid and Interface Science, 2022. …”

Section: Figurementioning

confidence: 99%

Nitric Oxide-Releasing Platforms for Treating Cardiovascular Disease

Wang

et al. 2022

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…The NO can be the power source of the nano/micromotors. Tao et al [ 78 ] designed NO-driven silica nanomotors with bowl-shaped mesoporous structures targeted to the thrombus surface through the modification of arginine-glycine-aspartate (RGD) polypeptides and simultaneous loading with L-arginine (LA) and the thrombolytic drug UK ( Figure 3 c, Table 3 ). LA reacted with excess ROS in the thrombus microenvironment to generate NO, thereby propelling the movement of nanomotors.…”

Section: Nano/micromotors In Blood Vesselsmentioning

confidence: 99%

Applications of Nano/Micromotors for Treatment and Diagnosis in Biological Lumens

et al. 2022

View full text Add to dashboard Cite

Natural biological lumens in the human body, such as blood vessels and the gastrointestinal tract, are important to the delivery of materials. Depending on the anatomic features of these biological lumens, the invention of nano/micromotors could automatically locomote targeted sites for disease treatment and diagnosis. These nano/micromotors are designed to utilize chemical, physical, or even hybrid power in self-propulsion or propulsion by external forces. In this review, the research progress of nano/micromotors is summarized with regard to treatment and diagnosis in different biological lumens. Challenges to the development of nano/micromotors more suitable for specific biological lumens are discussed, and the overlooked biological lumens are indicated for further studies.

show abstract

“…3.4 0.8 (J)R MnO 2 -NS and SH-SY5Y neuroblastoma cells Motors have shown the ability to scavenge toxic substances in both cell cultures and animal models. 66,67 Our aim was to illustrate that 0.8 JR MnO 2 -NS could be used for the faster removal of H 2 O 2 compared to 0.8 R MnO 2 -NS from the extracellular medium due to the higher locomotion of the former assemblies. Consequently, the viability of SH-SY5Y neuroblastoma cells in the proximity and exposed to H 2 O 2 was expected to be better preserved in the presence of 0.8 JR MnO 2 -NS as it was previously reported for MnO 2 nanoparticle-loaded polymersome-based nanomotors.…”

Section: Interaction Of 7 R Mno 2 -Ns and Sh-sy5y Neuroblastoma Cellsmentioning

confidence: 99%

Manganese dioxide nanosheet-containing reactors as antioxidant support for neuroblastoma cells

et al. 2022

View full text Add to dashboard Cite

show abstract

Nitric oxide-driven nanomotors with bowl-shaped mesoporous silica for targeted thrombolysis

Cited by 27 publications

References 33 publications

Nitric Oxide-Releasing Platforms for Treating Cardiovascular Disease

Nitric Oxide-Releasing Platforms for Treating Cardiovascular Disease

Applications of Nano/Micromotors for Treatment and Diagnosis in Biological Lumens

Manganese dioxide nanosheet-containing reactors as antioxidant support for neuroblastoma cells

Contact Info

Product

Resources

About